How Hydrofluoroalkane Propellants Work in Inhalers

Hydrofluoroalkane, usually abbreviated HFA, is a class of fluorinated propellant gas that replaced ozone-destroying chlorofluorocarbons (CFCs) in pressurized metered-dose inhalers and other aerosol products. The two HFAs approved for medical use are HFA-134a and HFA-227, and between them they now power virtually every puffer-style inhaler prescribed for asthma and chronic obstructive pulmonary disease worldwide. The switch was driven by international environmental law, but it also forced pharmaceutical companies to redesign their formulations from the ground up, producing some unexpected clinical benefits along the way.

How HFAs Came to Replace CFCs

The Montreal Protocol, established in 1987, committed nations to phasing out substances that deplete the ozone layer. CFCs were among the worst offenders, and their commercial uses were progressively banned. Metered-dose inhalers received a temporary exemption because millions of people with asthma and COPD depended on them, but the writing was on the wall: the pharmaceutical industry needed a CFC-free propellant.¹ Two hydrofluoroalkane propellants emerged as viable replacements. HFA-134a (1,1,1,2-tetrafluoroethane) and HFA-227 (1,1,1,2,3,3,3-heptafluoropropane) were selected because they share similar boiling points and vapor pressures with the CFC propellants they were replacing, which meant inhalers could keep roughly the same canister design and metering valve.²

The critical difference is that HFAs contain no chlorine. Without chlorine atoms, they cannot catalyze the breakdown of stratospheric ozone. That single chemical distinction is why the switch mattered for the atmosphere. But HFAs are not chemically identical to CFCs in every other respect either, and the differences created real headaches for formulators.

Why Reformulating Was Not Just Swapping One Gas for Another

HFAs are more polar than the CFCs they replaced. That sounds like a minor detail, but it changes how drugs and stabilizing agents behave inside the canister. Traditional surfactants that kept drug particles evenly suspended in CFC propellants did not dissolve well in HFAs, meaning inhaler makers had to find new surfactants or add co-solvents like ethanol to make everything play nicely together.³ Work on HFA-227 formulations showed that adding just one percent ethanol as a co-solvent made a wide range of surfactants and solvents miscible, opening up practical paths for stabilizing drug suspensions.⁴

Some companies took a different approach entirely. Rather than suspending micronized drug particles in the propellant the way CFC inhalers had, they dissolved the drug directly in the HFA (sometimes with the help of ethanol), creating a true solution formulation. This turned out to be more than a workaround. Solution-based HFA inhalers produce a fundamentally different aerosol spray than the old suspension-based CFC devices, and that difference has meaningful consequences for where the drug ends up in your lungs.

Smaller Particles and Deeper Lung Reach

The size of the particles an inhaler produces determines how deep they penetrate into the airways. Larger particles tend to slam into the back of the throat and never reach the lungs, while smaller particles ride the airstream into the peripheral airways where much of the inflammation in asthma actually lives. HFA solution formulations can generate considerably finer aerosol droplets than the old CFC suspensions. One well-studied example is QVAR, an HFA-beclomethasone dipropionate inhaler that produces particles with a mass median aerodynamic diameter of about 1.1 micrometers, compared with roughly 3.5 to 4.0 micrometers from its CFC predecessor.⁵ Those smaller particles deposit in the lung to a greater extent, and particularly in the small airways, which are a major site of airway inflammation.

Research on propellant blends confirmed that the vapor pressure of the propellant mixture itself plays a role: higher-vapor-pressure blends tend to produce smaller aerosolized particles.⁶ This means formulators have some ability to tune particle size by adjusting propellant composition, giving them a design lever that was harder to exploit with the older CFC systems.

Clinical Performance Compared with CFC Inhalers

The original regulatory bar was straightforward: HFA inhalers had to be at least as safe and effective as their CFC equivalents. They cleared that bar, but some HFA formulations did more than match their predecessors. Alternatives to CFC-containing inhalers were shown to be as safe and effective, and in certain respects they offered advantages over the older devices.⁷

The extrafine-particle HFA beclomethasone formulations drew particular attention. In a head-to-head switching study, patients who moved from CFC-beclomethasone to HFA-beclomethasone at half the previous dose maintained equivalent asthma control over eight weeks, with no increase in symptoms or acute episodes.⁸ A 12-week trial examining bronchial responsiveness found that the HFA formulation provided better control than the CFC version at the same daily dose, with the improved peripheral lung deposition presumed to play the key role.⁹

A large observational study looking at real-world outcomes over a full year found that patients starting or stepping up to extrafine HFA-beclomethasone were more likely to achieve asthma control than those on CFC-beclomethasone. The study concluded that the extrafine formulation could be used at half the dose of the large-particle version with at least as good clinical outcomes.¹⁰ Halving the steroid dose while keeping the same clinical result is a genuine practical benefit, because lower steroid exposure reduces the risk of side effects like oral thrush and hoarseness.

The Softer Spray and the Cold-Freon Effect

If you have ever used an older CFC inhaler and felt a sudden blast of cold gas hit the back of your throat, you experienced what clinicians call the cold-Freon effect. That cold, forceful plume often caused patients to reflexively stop inhaling, which meant less drug actually reached the lungs. CFC inhalers produced extremely forceful and cold plumes, and this was a recognized barrier to good inhaler technique.¹¹

Several HFA-based inhalers produce considerably softer and warmer plumes, though the improvement is not universal across all products. Detailed measurements of two HFA-driven combination inhalers showed dramatic differences even between HFA formulations. One product had a maximum plume velocity of about 10 meters per second at the approximate distance between mouthpiece and throat, while another hit roughly 15.5 meters per second. The minimum temperature the spray reached differed even more strikingly: about +6°C for one product versus nearly −38°C for the other.¹² So the propellant alone does not determine the spray experience; the overall formulation and device design matter enormously. A patient who finds one HFA inhaler uncomfortable may have a very different experience with another.

Safety of the Propellant Itself

When HFAs were introduced, there was an obvious question: is it safe to inhale a fluorinated gas several times a day, every day, for years? A 28-day controlled safety study of HFA-134a in healthy subjects found no clinically meaningful changes in blood pressure, heart rate, ECG readings, lung function, or blood chemistry. The propellant was detectable in blood within a minute of inhalation but dropped to a tenth of that level within 18 minutes, showing rapid clearance.¹³ Decades of subsequent widespread use have not raised new red flags. For the individual patient, HFA propellants are considered well tolerated.

The Greenhouse Gas Problem

HFAs solved the ozone problem but introduced a different environmental concern. While they do not damage the ozone layer, HFA-134a and HFA-227 are potent greenhouse gases with global warming potential many times that of carbon dioxide.¹⁴ In the United Kingdom, where the National Health Service tracks its carbon output in detail, metered-dose inhalers account for roughly 3 to 4 percent of the entire NHS’s carbon footprint.¹⁵ That is a striking number for a single class of medical device.

A comparison between metered-dose inhalers and dry powder inhalers illustrates the scale of the difference. Because dry powder inhalers use no propellant at all, estimated carbon-equivalent emissions per year for maintenance treatment were about 97 percent lower with a dry powder device than with a pressurized metered-dose inhaler. For reliever medication among asthma patients, the gap was even wider, at roughly 99.6 percent lower, amounting to savings of about 131 kilograms of CO₂-equivalent annually per patient.¹⁶ Soft mist inhalers are also propellant-free and therefore have minimal emissions.¹⁷

There is also a subtler atmospheric concern. When HFA-134a and HFA-227 break down in the atmosphere through reaction with hydroxyl radicals, one of the end products is trifluoroacetic acid, or TFA. This persistent chemical accumulates in waterways and soils.¹⁸ At current concentrations TFA is not considered an acute hazard, but it is extremely resistant to further degradation, which means it builds up over time. Whether long-term accumulation poses ecological risks is still debated.

The Kigali Amendment and Rising Costs

The same Montreal Protocol that phased out CFCs has been extended to address HFAs (technically classified as hydrofluorocarbons, or HFCs, in the regulatory framework). The Kigali Amendment, adopted in 2016, mandates a global phase-down of HFC production and consumption. HFA propellants used in medical inhalers are not outright banned, but as non-medical uses of the same chemicals are curtailed, a knock-on effect on supply and pricing is expected. Projections estimated that the reduction in non-medical propellant uses could lead to roughly a five-fold increase in propellant costs for inhaler manufacturers, with the impact hitting Western markets around 2025.¹⁹ This economic squeeze, combined with the environmental pressure, has accelerated interest in two directions: switching patients to propellant-free devices where possible, and developing new propellants with a smaller climate footprint.

Next-Generation Propellants

Two leading candidates aim to replace HFA-134a while keeping the pressurized metered-dose inhaler format intact. Each takes a different chemical approach to slashing greenhouse warming potential.

HFA-152a

HFA-152a (1,1-difluoroethane) has a global warming potential roughly one-tenth that of HFA-134a. Safety trials in people with asthma have been encouraging. A crossover study of 25 participants found that lung function after inhaling HFA-152a was statistically equivalent to HFA-134a, with fewer participants reporting side effects in the HFA-152a arm (4 percent versus 12 percent), and none of the events were serious. A separate mucociliary clearance study in 20 subjects found no meaningful difference between the two propellants.²⁰

A larger trial, the TRECOS study, randomized 553 patients with asthma to receive a triple combination therapy (beclomethasone/formoterol/glycopyrronium) delivered via either HFA-152a or HFA-134a. Completion rates were high in both arms, and there was no meaningful difference in lung function between groups. Adverse events were actually somewhat less common with HFA-152a (about 19 percent versus 28 percent), and most were mild or moderate.²¹ The main practical hurdle with HFA-152a is that it is mildly flammable, which requires engineering changes to manufacturing lines and canister design.

HFO-1234ze(E)

HFO-1234ze(E) is a hydrofluoroolefin, technically a different chemical class, with near-zero global warming potential. A randomized crossover study in participants with asthma found that an HFO-1234ze metered-dose inhaler was well tolerated, with no significant effects on lung function and no bronchospasm events, matching the performance of an HFA-134a device.²² A phase 3 trial in COPD patients tested a full triple-therapy combination delivered via HFO-1234ze against the same drug delivered via HFA-134a and concluded that the new propellant could replace the old one, supporting further real-world evaluation.²³ HFO-1234ze is not flammable, which gives it a manufacturing advantage over HFA-152a, but it has a lower vapor pressure, which complicates formulation design in different ways.

The Prescriber’s Tradeoff

Switching everyone from metered-dose inhalers to dry powder or soft mist devices sounds like an obvious environmental win, but it is not that simple. Dry powder inhalers require a strong, fast inhalation to generate the force that breaks the powder into respirable particles. Young children, elderly patients, and people in the middle of a severe asthma attack often cannot produce that breath. For those patients, a pressurized metered-dose inhaler, which delivers the drug under its own propellant pressure, remains the most reliable option. Rescue inhalers in particular are dominated by metered-dose devices because they work regardless of how weak the patient’s breathing effort is.

An analysis of NHS prescription data in England found that switching from high-warming-potential metered-dose inhalers to the least expensive low-warming-potential alternatives within each therapeutic category could produce major financial savings alongside large carbon reductions. Most of the savings came from switching more expensive combination maintenance inhalers to dry powder equivalents.²⁴ But the picture gets more nuanced when you look at what clinicians actually value. A discrete choice experiment found that healthcare providers ranked clinical outcomes, particularly fewer exacerbations and low side effects, as the most important factors when choosing an inhaler. Low global warming potential was a meaningful driver of choice but not the dominant one. Providers were willing to choose a higher-warming-potential inhaler if it reduced exacerbation rates, even at higher cost to the patient.²⁵

This tension is where the next-generation propellants become most relevant. If HFA-152a or HFO-1234ze can deliver equivalent clinical performance with a fraction of the climate impact, the whole tradeoff dissolves. Patients who need or prefer a pressurized metered-dose inhaler could keep using one without contributing disproportionately to greenhouse gas emissions. Both propellant candidates are in late-stage clinical development, and the first products could reach the market within the next few years.

How HFA Inhalers Differ from Each Other

One thing worth understanding is that “HFA inhaler” is not a single product category with uniform characteristics. Two inhalers can both use HFA-134a as a propellant and still deliver very different experiences. The drug can be in suspension or in solution. The particle size can range from extrafine (around one micrometer) to conventional (three to five micrometers). The plume can be cold and forceful or warm and gentle. The co-solvents and surfactants in the formulation affect taste, spray feel, and drug stability.

This matters practically because patients sometimes assume that all inhalers in a class are interchangeable. They are not. A patient who was doing well on one HFA-beclomethasone product and is switched to a different HFA-beclomethasone product may notice changes in spray feel, taste, and even clinical control if the particle-size profile differs. The solution-based extrafine formulations tend to deposit more drug in the peripheral airways, while suspension-based formulations with larger particles deposit more in the central airways. Depending on where in the lung the inflammation is most active, one profile may work better than the other for a given individual. If your inhaler is changed and your symptoms shift, it is worth raising that with whoever prescribed it rather than assuming all versions of the same drug are identical.